The drug eculizumab, a synthetic antibody that inhibits the inflammatory response, significantly reduced the risk of relapse with neuromyelitis optica spectrum disorder (NMOSD). This rare but severe ...

Please provide your email address to receive an email when new articles are posted on . Ultomiris is a C5 complement inhibitor for neuromyelitis optica spectrum disorder. Trial patients did not ...

TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that results from the phase III study of satralizumab (development code: SA237), SAkuraSky Study (NCT02028884), were ...

LONDON--(BUSINESS WIRE)--Technavio has announced their latest drug pipeline analysis report on neuromyelitis optica (Devic’s syndrome). The report includes a detailed analysis of the pipeline ...

(RTTNews) - The European Commission has approved Horizon Therapeutics plc's (HZNP) Uplizna or inebilizumab for the treatment of adults with Neuromyelitis Optica Spectrum Disorder. Uplizna is indicated ...

Neuromyelitis optica spectrum disorder (NMOSD)—an autoimmune disease of the optic nerve, spinal cord, or both, which can result in blindness or paralysis—may result in insulin resistance, a new study ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...

BARCELONA, Spain — Use of ravulizumab for long-term treatment of neuromyelitis optica spectrum disorder (NMOSD) offered sustained protection from relapse for at least 3 years, results from the ...

EUFAULA, Ala. (WRBL) – Students and faculty at Eufaula Primary School rallied behind their PE teacher, Carla Douglas, after her life-altering diagnosis with Neuromyelitis optica spectrum disorder.

(RTTNews) - Roche (RHHBY) said Monday that the U.S. Food and Drug Administration has approved ENSPRYNG for Neuromyelitis Optica Spectrum Disorder or NMOSD. The First and only FDA-approved subcutaneous ...